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Abstract 
Aims 
To evaluate physicians' adjustments of insulin pump settings based on continuous glucose monitoring 
(CGM) for patients with type 1 diabetes and to compare these to automated insulin dose adjustments. 
Methods 
A total of 26 physicians from 16 centres in Europe, Israel and South America participated in the study. 
All were asked to adjust insulin dosing based on insulin pump, CGM and glucometer downloads of 
15 patients (mean age 16.2 ± 4.3 years, six female, mean glycated haemoglobin 8.3 ± 0.9% [66.8 ± 
7.3 mmol/mol]) gathered over a 3‐week period. Recommendations were compared for the relative 
changes in the basal, carbohydrate to insulin ratio (CR) and correction factor (CF) plans among 
physicians and among centres and also between the physicians and an automated algorithm, the 
Advisor Pro (DreaMed Diabetes Ltd, Petah Tikva, Israel). Study endpoints were the percentage of 
comparison points for which there was full agreement on the trend of insulin dose adjustments (same 
trend), partial agreement (increase/decrease vs no change) and full disagreement (opposite trend). 
Results 
The percentages for full agreement between physicians on the trend of insulin adjustments of the 
basal, CR and CF plans were 41 ± 9%, 45 ± 11% and 45.5 ± 13%, and for complete disagreement 
they were 12 ± 7%, 9.5 ± 7% and 10 ± 8%, respectively. Significantly similar results were found 
between the physicians and the automated algorithm. The algorithm magnitude of insulin dose change 
was at least equal to or less than that proposed by the physicians. 
Conclusions 
Physicians provide different insulin dose recommendations based on the same datasets. The 
automated advice of the Advisor Pro did not differ significantly from the advice given by the 
physicians in the direction or magnitude of the insulin dosing. 
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1 INTRODUCTION 
Insulin dose adjustments are an important part of the diabetes management needed to achieve target 
glycaemic control, as insulin dose requirements change frequently.1 These adjustments are based 
mainly on detailed glucose data: capillary blood glucose and/or continuous glucose monitoring 
(CGM) data, and insulin delivery and meal data, such as carbohydrate intake. The increasing use of 
insulin pumps and CGM enables easy gathering of these valuable data from the devices. 
Indeed, the number of patients who use insulin pump therapy is constantly growing and, currently, it 
is estimated that more than a million patients around the world use this treatment method.2 According 
to the Type 1 Diabetes Exchange registry, 50% of patients with type 1 diabetes in the United States 
use insulin pump therapy.3 The rate of pump use is similar in Europe, with some centres reaching 
rates between 70% and 93%.4 Studies have shown that insulin pump therapy may be associated with 
improved overall metabolic control compared with multiple daily injections, improved glycated 
haemoglobin (HbA1c) levels5, 6 and reduced rates of severe hypoglycaemia.5-7 
Optimal utilization of pump therapy requires the studying and application of a combination of 
theoretical knowledge and practical skills from all stakeholders, including the treating physicians, the 
diabetes educators, the patients and their caregivers. There is an ongoing need to tailor the pump 
settings, namely, the insulin correction factors (CFs), carbohydrate to insulin ratios (CRs), basal plan 
and insulin activity time, in order to optimize and improve glucose control. Retrospective analysis of 
CGM data can be a valuable means of guiding adjustments of these pump settings.8 Nevertheless, 
analysis of this multitude of information may be overwhelming for many patients, caregivers and 
healthcare providers, as it requires extensive training and considerable time. Furthermore, there are 
limited data and no uniform guidelines to direct prescribers and patients regarding ways to optimize 
the parameters of the insulin pump settings and CGM.9, 10 The lack of concrete guidelines leads to 
dose adjustments being made subjectively by healthcare professionals, which are based mostly on 
their individual experience and therefore greatly variable. 
Diabetes care faces tremendous changes, as new technologies are emerging to help patients and 
healthcare providers cope better with daily tasks. These technological improvements include new 
apps, connected devices, medical platforms, big data and health analytics and decision support 
algorithms. Their incorporation into management paradigms may improve diabetes control, and 
patients' health and quality of life.11 
Insulin and glucose data can be analysed by sophisticated algorithms and by artificial intelligence in 
order to detect individual glucose patterns as well as pitfalls in diabetes management and to suggest 
lifestyle and insulin dosing adjustments accordingly. The use of design support algorithms and 
telemedicine are emerging as tools to help adjust insulin dosing during and between visits.8, 12, 13 
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The Advisor Pro (DreaMed Diabetes Ltd, Petah Tikva, Israel), is a decision support software device, 
designed to assist healthcare professionals in decision‐making when treating patients with type 1 
diabetes who use insulin pump therapy and monitor their glucose levels using CGM. The Advisor 
Pro analyses data from various devices (CGM device, glucometer and insulin pump) and provides 
recommendations for insulin pump dosing adjustments, including a basal plan, CR plan and CF plan. 
In addition, it provides behavioural recommendations related to the way the patient delivers insulin 
and manages diabetes. The Advisor Pro has been clinically tested in a feasibility study. This was a 
single‐centre study that included 13 patients with type 1 diabetes who used insulin pumps and CGM. 
Patients were randomly assigned to participate either in a group in which insulin pump adjustments 
were guided by a physician (control group) or a group that was guided by the Advisor Pro 
(intervention group). Insulin titration was performed every 3 weeks and endpoints were measured at 
the end of 3 months' intervention. No difference was found in the average time within range (70‐180 
mg/dL) and time in hypoglycaemia (<70 mg/dL) between the two groups at the end of the study. The 
proportion of time spent within range for the intervention group was 52% at baseline and 57% after 
3 months, and in the control group it was 57% both at baseline and after 3 months. The time spent in 
hypoglycaemia decreased from 3.4% at baseline to 2.5% at the end of the study for the intervention 
group and from 4.9% to 4.3% for the control group.14 
The aim of the present study was to compare recommendations for insulin pump settings made by 
different physicians treating patients with diabetes, in order to evaluate the extent of consistency 
among them. In addition, we compared the physicians' recommendations to those given by the 
automated software, the Advisor Pro. 
2 MATERIALS AND METHODS 
This was a multicentre, multinational non‐interventional survey study. The study protocol was 
approved by the Rabin institutional review board (No. 000917). 
We used the CareLink Pro Ver 4.0A (4.0.2504.1) diabetes data management (Medtronic Diabetes, 
Northridge, California) uploads of 15 patients, including CGM, self‐monitoring of blood glucose and 
insulin pump data for 3 weeks, from the Institute for Endocrinology and Diabetes at Schneider 
Children's Medical Centre. Each physician received an anonymized dataset in a PDF file, as well as 
general de‐identified information about the patient, including gender, age, HbA1c level, weight, 
height and body mass index. Physicians received details about the current pump settings of each 
patient (ie, basal rate plan, CR plan, CF plan, glucose targets and active insulin time). Each physician 
was asked to provide her/his proposed recommended changes to insulin pump settings and asked to 
state if any behavioural or lifestyle changes were recommended. All recommendations were provided 
in a uniform format on specialized forms given to each physician. An example of the form is provided 
in Appendix S2. 
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The cohort of physicians who participated in the study included nine consultants from three centres 
(in Israel, Slovenia and Germany) and 17 out of 30 physicians who participated in the European 
Society for Paediatric Endocrinology Diabetes, Obesity and Metabolism School held in April 2017 
in Rome, Italy. 
2.1 Data analysis 
To compare the different recommendations of the physicians, the recommended daily adjustments 
were divided into 24 hourly periods (1 hour each) for basal, CR and CF plans, resulting in a total of 
1080 comparison points (24 hours, 15 patients, three plans). 
The physicians' recommendation points were compared for the relative changes to the patient's 
current pump settings in the basal, CR and CF plans between the physicians, between and within 
centres and between the physicians and the automated Advisor Pro algorithm. 
The primary endpoints of the study were the percentage of comparison points in which there was full 
agreement on the trend of insulin dose adjustment (increase, decrease or no change) and full 
disagreement (opposite directions of insulin dose adjustments). Secondary endpoints were the 
percentage of comparison points that were in partial disagreement, divided into two categories, partial 
positive disagreement (increase insulin dose vs no change) and partial negative disagreement 
(decrease insulin dose vs no change). 
Additional comparisons in pump setting adjustments were performed, comparing recommendations 
given by physicians based at the same centre, or given by faculty physicians vs fellow physicians, or 
given by physicians who practise in centres with high rates of pump use (>50%) vs those with lower 
pump use rates (Appendix S1). 
2.2 Statistical analysis 
A one‐tailed, non‐inferiority t test was used to assess whether the agreement (right tail) and the 
disagreement (left tail) between physicians and the Advisor Pro (26 pairs and total of 28 080 
comparison points) was not inferior to the agreement and disagreement between pairs of physicians 
(351 pairs and total of 379 080 comparison points). The non‐inferiority margin for the agreement t test 
was set as the 25th percentile of the distribution of the level of agreement between one physician and 
his/her colleague (351 pairs and total of 379 080 comparison points) per parameter. The non‐
inferiority margin for the disagreement t test was set as the 75th percentile of the distribution of the 
level of disagreement between one physician and his/her colleague (351 pairs and total of 379 080 
comparison points) per parameter. The null hypothesis was that there is a difference in 
agreement/disagreement between physicians and the Advisor Pro, therefore, any significant P value 
(P<0.05) indicated that there was no significant difference between the physicians and Advisor Pro 
recommendations, indicating non‐inferiority of the Advisor Pro. The number of similar or dissimilar 
time periods for each parameter basal, CR and CF change from the original programme, were 
compared among physicians and the Advisor Pro using general linear model repeated‐measures 
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analysis with pairwise comparisons. The number of parameters that were changed for the same period 
of time among physicians and the Advisor Pro were compared using Pearson's χ2 tests. The magnitude 
of the insulin dose adjustment between physicians and the Advisor Pro for the three variables (basal, 
CR and CF) was compared using a one‐tailed, non‐inferiority t test. The null hypothesis was that the 
magnitude of the difference in dose adjustments between physicians and the Advisor Pro was greater 
than the magnitude of the difference in dose adjustments between each pair of physicians, therefore, 
any significant P value (P < 0.05) indicated non‐inferiority of the difference between physicians and 
the Advisor Pro in magnitude of insulin dose adjustments. The non‐inferiority margin was the 75th 
percentile of the mean absolute difference. 
3 RESULTS 
A total of 25 paediatric physicians and 1 adult physician participated in the present survey study: 20 
physicians from Europe (eight from Italy, four from Slovenia, three from Germany, three from the 
UK, 1 from Croatia and 1 from Poland), five physicians from Israel and one physician from Brazil. 
All participating physicians were active providers of diabetes patient care and were affiliated with 16 
different centres that are experienced with insulin pump adjustments. The levels of experience of the 
physicians and their institutions, and the characteristics of the 26 participating physicians are 
presented in Table S1 in Appendix S1. 
The characteristics of the patients whose data were used for the present survey are presented in 
Table S2 in Appendix S1. The downloads included data from 10 paediatric patients and five young 
adults (mean age 16.2 ± 4.3 years, six female, mean HbA1c 8.3 ± 0.9% [66.8 ± 7.3 mmol/mol]). All 
physicians completed the 15 forms of patients' pump recommendations, giving a total of 390 forms. 
3.1 Degree of agreement in treatment adjustments 
The proportion of full agreement between physicians on the direction of insulin adjustments of the 
basal, CR and CF settings was quite low and similar across the three assessed settings, within the 
range of 41% to 46% (Table 1). The similarity to the recommendations of the algorithm was 
significant, and full agreement was also within approximately the same range, at 41% to 48% (P < 
0.01 for all three parameters; Figure 1A). The proportion of complete disagreement was notably lower 
than the proportion of full agreement and did not differ much between the parameters (range 9.5%‐
12%). Complete disagreement with the software tended to be lower than that between physicians for 
the CF plan (3.5%, P = 0.03), and similar for the two other plans, within a range of 8.5%‐10% (P < 
0.01 for both; Figure 1B). 
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Table 1. Results of comparisons for primary and secondary endpoints 
 
 
Among 
physicians 
Between Advisor 
Pro and physicians 
P 
 
Primary endpoints (complete agreement) 
   
Agreement on basal change direction, % 41 ± 9 41.5 ± 8 <0.01 
Agreement on CR change direction, % 45 ± 11 48 ± 11 <0.01 
Agreement on CF change direction, % 45.5 ± 13 43.5 ± 11 <0.01 
Disagreement on basal change direction, % 12 ± 7 10 ± 6 <0.01 
Disagreement on CR change direction, % 9.5 ± 7 3.5 ± 2 <0.01 
Disagreement on CF change direction, % 10 ± 8 8.5 ± 5 0.03 
Secondary endpoints (partial agreement) 
   
One recommendation to increase/decrease basal 47 ± 8 48.5 ± 6 <0.01 
insulin dose vs no change, %    
One recommendation to increase/decrease CR insulin 45.5 ± 12 48.5 ± 10 <0.01 
dose vs no change, %    
One recommendation to increase/decrease CF insulin 45 ± 12 48 ± 9 <0.01 
dose vs no change, %    
Abbreviations: CF, correction factor; CR, carbohydrate to insulin ratio. 
Values are mean ± SD. 
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Figure 1. Primary endpoints: Level of complete agreement/disagreement. A, Level of agreement. B, 
Level of disagreement per pump settings. Box plot represents the physician‐physician comparisons 
showing the median, interquartile range, minimum and maximum (n = 351) per pump setting feature. 
Dots represents the Advisor Pro‐physician comparisons (n = 26) per pump setting feature. A non‐
significant difference was found between the level of agreement/disagreement among physicians and 
between physicians and the Advisor Pro (A: P < 0.01 all parameters, B: P < 0.01 for basal and 
carbohydrate to insulin ratio [CR] parameters and 0.03 for the correction factor [CF]) 
 
 
The proportions of partial agreement (to increase/decrease insulin dose vs no change) between 
physicians were similar to those observed for full agreement, and similar across recommendations 
(within the range of 45%‐47%; Table 1). A significant similarity was found with the 
recommendations of the algorithm, and the proportion of partial agreement was ~48% across 
recommendations (Table 1). 
Physicians working within the same centre were not found to provide similar recommendations. The 
level of agreement between physicians was 51.7%, 47.8% and 50.8% for sites 1, 2 and 3, respectively. 
The disagreement level was 4.2%, 4.7% and 9.2% for sites 1, 2 and 3, respectively. A significant 
difference (P = 0.018) in the distribution of the level of agreement/partial agreement/disagreement 
was found among the three different centres (Figure S1 in Appendix S1). 
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The level of centre experience with insulin pump use had no effect on degree of agreement; the results 
were similar between physicians in centres in which <50% patients were using insulin pumps (n = 
12) and those in which >50% of the patients were using insulin pump therapy (n = 14). The seniority 
of physicians did not affect the agreement either. Similar results were also found between faculty 
physicians (n = 13) and fellows (n = 13; Table S3 in Appendix S1). 
3.2 Magnitude of treatment adjustments 
Figure 2 presents the median magnitude of change and the interquartile range of the increase and 
decrease in insulin dose adjustments for each of the three insulin‐pump setting parameters. On 
average, in the cases in which physicians were in full agreement about the recommended direction of 
change, they tended to recommend small adjustments in the basal setting and an adjustment of ~20%‐
30% in CR and CF. A significantly similar magnitude of change was found between the Advisor Pro 
and the physicians' recommendations for the 3 variables: basal (P = 0.002), CR (<0.001) and CF 
(<0.001). The overall range from the minimal to the maximal recommended changes between the 
different physicians in the magnitude of recommended change was 94% larger than between the 
physicians and the Advisor Pro. 
 
 
 
Figure 2. Magnitude of insulin pump dosing adjustments in cases of full agreement for basal, 
carbohydrate to insulin ratio (CR) and correction factor (CF) plans. Box plot represents the median, 
interquartile range, minimum and maximum (n = 351) per pump settings feature. The non‐inferiority 
margin was 75th percentile of the mean absolute difference. A non‐significant difference was found 
in the magnitude of change in cases of full agreement among physicians and between physicians and 
the Advisor Pro (P = 0.002 for basal and P < 0.01 for the CR and CF) 
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The magnitude of the relative dose adjustments (as a percentage) in cases of agreement in the direction 
of dose adjustment (increase or decrease) was found to be non‐inferior between physicians and the 
Advisor Pro during the day as well as during the night (Table S4in Appendix S1); therefore, according 
to the null hypothesis, the magnitude of change of the Advisor Pro was at least equal to or less than 
the advised magnitude of change proposed by the physicians. 
3.3 Number of time periods and insulin dosing parameter adjustments 
Physicians tended to increase the number of basal periods: mean ± SD from 4.4 ± 1.5 to 4.9 ± 0.6 
(P = 0.11) vs 7.7 ± 1.9 for the Advisor Pro (P < 0.001). The number of CR plan periods were changed 
by the physicians from 2.7 ± 1.4 to 3.2 ± 0.6 (P = 0.07) compared with 3.9 ± 1.3 for the Advisor Pro 
(P < 0.01). The number of CF plan periods were significantly changed by the physicians from 1.9 ± 
1 to 2.3 ± 0.5 (P = 0.012) compared with 3.5 ± 1.1 for the Advisor Pro (P < 0.01; Table 2). 
 
 
Table 2. Number of basal, carbohydrate to insulin ratio and correction factor rate periods of time 
 
Insulin pump setting Mean (SD) number of time periods P 
Original Physicians Advisor Pro 
 
Basal 
 
4.4 (1.5)a 
 
4.9 (0.6)a 
 
7.7 (1.7)b 
 
<0.001 
CR 2.7 (1.4)a 3.2 (0.6)a 3.9 (1.3)b 0.001 
CF 1.9 (1)a 2.3 (0.5)b 3.5 (1.1)c 0.001 
Rates with different superscripts (a, b, c) differ significantly from each other in that row at P< 0.05 
(adjustment for multiple comparisons: least significant difference). Abbreviations: CF, correction 
factor; CR, carbohydrate to insulin ratio. 
General linear model, repeated measures with analysis of pairwise comparisons. 
 
 
In instances where there was a decision to change insulin dose, physicians tended to change one, two 
or three variables (basal, CR or CF) at the same period of time in 28.5%, 33.5% and 23%, compared 
with 24.5%, 27% and 16.5% of cases, respectively, for the Advisor Pro (P < 0.001). 
  
10 
 
4 DISCUSSION 
Substantial diversity was found among different physicians in insulin dose recommendations made 
for pump settings based on CGM data. The overall level of agreement in the direction of insulin dose 
adjustment was only ~45% for each of the pump variables (basal, CR and CF). This level of 
agreement did not differ, even when physicians were based in the same centre or among centres with 
high frequency of pump use. The automated advice given by the Advisor Pro did not differ 
significantly from the advice given by the physicians in the direction and magnitude of the insulin 
dosing. 
Physicians within the same centre were also found to agree only on approximately half of the 
recommended changes; thus, even in centres with experience in diabetes technology, incorporating 
multidisciplinary teams, educational models and defined glucose target goals, there was a diversity 
in decision‐making regarding insulin dose adjustments. An even more interesting finding was the 
level of complete disagreement, as some physicians wanted to increase the insulin dose at a point 
where others suggested reducing the dose. The level of disagreement was found to be somewhat 
higher for the basal decisions than for the CR and CF decisions. Among centres that were studied, 
the level of complete disagreement differed significantly and reached as high as >10% of overall 
decisions at one site. 
The physicians as well as the Advisor Pro tended to advise an increase in the overall dose of insulin, 
more by modification of the CR and CF doses than by modification of the basal insulin doses; thus, 
more insulin may be given as boluses and less as basal doses. The finding that more insulin should 
be delivered as boluses than as basal doses has been observed in pump15 and closed‐loop16 studies 
and was found to be associated with better glycaemic control and HbA1c levels. 
The Advisor Pro recommendations were more conservative with respect to magnitude of change in 
insulin dosing because of the safety limits of the system. The median and interquartile range 
percentage of change for each variable (basal, CR and CF) was similar between the Advisor Pro and 
physicians. Nevertheless, some physicians recommended changes of a larger magnitude in both 
directions as high as 150% increase in insulin dosing. The percentage of change in dose 
recommendations of the Advisor Pro did not exceed beyond that of the physicians. The Advisor Pro 
adjusted the pump settings in small steps because of its inherent safety measures. The magnitude of 
change is more permissive in cases of hypoglycaemia, as fewer events are needed to reduce the 
amount of insulin dose as compared to hyperglycaemic events. A recently published study showed 
that magnitude of dose changes by the physicians for 20 simulated patients on multiple daily 
injections and self‐monitoring of blood glucose were greater than by dedicated algorithms.17 This 
result points out the greater variability and challenges associated with managing patients on pumps 
using CGM. 
Data in the literature are scarce regarding differences between different prescribers in the amount of 
insulin dose adjustments. A study from the Netherlands evaluated factors that influenced the decision 
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of 190 care providers in basal insulin titration for patients with type 2 diabetes. Even for type 2 
diabetes, for which guidelines and official recommendations exist and adjustments are easier because 
only basal insulin is adjusted, insulin titration magnitude was found to be significantly different 
between providers.18 
Physicians tended to increase the number of periods of each pump setting parameter from the baseline 
settings; however, statistical significance was reached only for the CF. The Advisor Pro 
recommended adjustments for significantly more basal rates than did the physicians and to a lesser 
extent, for the CR and CF rates. The Advisor Pro uses a unique algorithm that estimates the insulin 
requirements and was therefore able to recommend significantly more time periods. Studies have 
shown the need for different insulin requirements throughout the day, which depend mainly on age 
and on the stage of puberty.19, 20 Insulin pump therapy can provide a basal delivery of insulin in a 
more physiological way and can mimic the circadian needs. A euglycaemic clamp study showed that 
it takes 2.5 to 4 hours until a considerable change in basal infusion leads to a new steady‐state 
level,21 therefore, up to 10 basal rates are effective with current insulin analogues. 
Another difference was found for the number of parameters that were simultaneously adjusted to 
increase the insulin dose within the same time frame. Physicians tend to change insulin dosing in 
more than one variable in the same time frame more often than the Advisor Pro. 
There were cases that physicians agreed upon more than others. For example, in one case, 92% of 
physicians suggested a decrease in the CF. In this particular case, the patient had several correction 
boluses which did not result in blood glucose‐lowering. The Advisor Pro provided the same 
recommendation. 
Dosing recommendation is one of the main tasks patients and healthcare providers deal with daily in 
diabetes management. Insulin dose adjustments are needed22, 23 and the newly available devices and 
the data they generate may help facilitate this process. Nevertheless, even with the recent availability 
of unified diabetes management platforms, this task remains challenging24. People with type 1 
diabetes, their caregivers and their healthcare providers are often overwhelmed by the information 
collected via these platforms. The ability to transform this amount of data into actionable knowledge, 
which could be used to adjust therapies and better manage daily activities, is still lacking. 
Additionally, the number of people with diabetes is rising worldwide, but the number of diabetes 
specialists has not kept pace with this increasing prevalence.25-27 The low frequency of patient‐
physician interactions (just once every 3‐4 months) and the fact that insulin profile optimization is 
very time‐consuming, even for experts, raise the need for a tool that can transform data into insulin 
therapy adjustments between clinic visits. The study made comparisons between physicians and 
automated dose adjustments based on digital data alone and not those given by care providers during 
face‐to‐face visits with patient input. The percentage of agreement between the automated system 
and the physicians might have been different if we had incorporated patients' input regarding exercise, 
stress, alcohol intake and so on. The lack of patient input will be addressed by using the next‐
generation advisors that may incorporate data gathered from the digital ecosystem (internet of things). 
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A few small‐scale studies have shown that insulin dose adjustments made by software for patients 
using multiple daily injections and self‐monitoring of blood glucose can be made safely and 
efficiently. The recommendations were found to be similar to what the caregivers would 
advise28, 29 and may reduce the need for additional clinic visits for patients with type 2 
diabetes.30 The present study supports the notion that an automated decision support system that can 
give automated advice on changing insulin pump settings provides similar recommendations to those 
given by experienced physicians, making it akin to another member in the healthcare team. In the 
future, this tool can be used to achieve better self‐management by giving its recommendations directly 
to the patients. In addition, as closed‐loop systems will become more available mainly for those who 
use pump and CGM, the main role of the Advisor Pro will be its use for those who are treated with 
an insulin pump and use self‐monitoring of blood glucose. 
The study is limited by the fact that it may not be possible to extrapolate the findings to other groups 
of physicians or prescribers, such as primary healthcare providers, nurses or diabetes educators. Our 
study population included adolescents and young adults and did not consider individual targets. That 
may have limited our ability to generalize the data to a broader population of people with type 1 
diabetes. Although the Advisor Pro should not act differently in other groups of patients, the 
magnitude of change may vary. We may have found even larger differences among physicians as 
well as between physicians and the Advisor Pro if these variables had been included as insulin dosing 
and requirements do vary with age. The effectiveness of the insulin dosing adjustments was not 
evaluated in the present study because the aim was to determine whether there was agreement on 
pump adjustments among experienced physicians. The effectiveness of the automated system was 
tested in a small feasibility study that showed similarity in outcomes between recommendations given 
by physicians and those given by the Advisor Pro.14 The algorithm effectiveness is being tested in a 
non‐inferiority, multicentre, multinational, parallel‐design study including 112 patients to evaluate 
the system's decisions compared to those made by physicians (ClinicalTrials.gov identifier: 
NCT03003806). 
The advantage of the present study was the number of physicians that participated in the survey from 
different centres, which enabled us to compare, for the first time, human and automated decisions in 
insulin pump setting adjustments. 
In conclusion, this survey showed that there was a wide variability in the ways experienced physicians 
chose to adjust insulin pump dosing and that automated adjustments did not differ from those given 
by different physicians in the direction and magnitude of insulin dosing. Future research assessing 
the clinical effects of recommendation strategies could serve as a basis for informed guidelines. 
Automated recommendations could serve as a tool for healthcare providers to make clinic visits more 
effective and to help adjust insulin dosing in‐between visits. 
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